Search Results for “diabetes” – Page 10 – media

Gan & Lee aims at the hypoglycemic drug market

Collective procurement ‘big winner’ In 1995, Gan Zhongru, who had worked as a postdoctoral fellow and senior biochemist at Merck&Co. in the United States, returned to China to start a business. Three years later, the team formed by Gan Zhongru developed China’s first genetically recombinant human insulin, becoming the third company after Eli Lilly and Novo Nordisk to produce and sell recombinant human insulin. Subsequently, under the leadership of Gan Zhongru and his R&D team, Gan Li Pharmaceutical continued to develop the first long-acting insulin analog, the first fast acting insulin analog, the first pre mixed insulin analog, and the first winter insulin in China. The products covered three insulin functional segments: long-acting, fast acting, and medium acting, becoming the “king of insulin” in China. With the acceleration of domestic insulin substitution in recent years, Ganli Pharmaceutical’s operating revenue has increased from 1.771 billion yuan in 2016 to 3.612 billion ...
- Source: drugdu
- 72
- November 8, 2024
The world’s first, created in China! Weekly insulin preparation Novozyme® debuts at CIIE, to be launched at the end of the month

On November 6, at the 7th China International Import Expo (hereinafter referred to as “CIIE”), Novo Nordisk held a press conference and announced that the world’s first weekly insulin formulation, Novozymes® (insulin Efficacy Injection), which was exhibited for the first time at this CIIE, will be commercially launched in China at the end of November 2024 for the treatment of type 2 diabetes in adults, ushering in the era of weekly insulin treatment. Professor Peng Yongde, head of the Department of Endocrinology and Metabolism at the First People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, said: “Insulin therapy is still an indispensable and important cornerstone in the diabetes management pathway. As a key component, basal insulin strives to better meet clinical treatment needs to help patients start treatment in a timely manner, improve treatment compliance, increase treatment continuity, and improve patient satisfaction.” Insulin “from day to week” ...
- Source: drugdu
- 56
- November 8, 2024
Cell Drug Conjugates – An Innovative Drug Delivery System

In recent years, cell drug conjugates (CDCs) have gradually become a hot topic in medical research as an emerging drug delivery system. On July 1, 2024, Professor Gu Zhen and others from Zhejiang University published a review paper titled “Cell Drug Conjugates” in the Nature Journal of Biomedical Engineering. The article deeply explores the principles, preparation methods, and applications of this technology in cancer and immune diseases. This article will explain the content of the literature in detail, taking you to understand the core and prospects of this innovative technology. 01 What are cell drug conjugates (CDCs)? Cell drug conjugates are a complex that combines live cells and therapeutic drugs, capable of simultaneously exerting the functions of both, particularly suitable for the treatment of complex diseases such as cancer and autoimmune disorders. Unlike traditional drug delivery systems such as liposomes, nanoparticles, etc., CDCs utilize the physiological characteristics of cells, ...
- Source: drugdu
- 55
- November 7, 2024
CIIE Observation | Eli Lilly’s Two “Focuses”

Today, the seventh CIIE opened grandly in Shanghai. Every year, the CIIE is an excellent opportunity for global pharmaceutical companies to showcase their latest research and development results and expand international markets, and it is also a core window for insight into Chinese market opportunities. This year will be no exception. So, let’s take a look at Eli Lilly, a pharmaceutical company with nearly 150 years of history, and its latest thinking. As an all-around warrior, this year Eli Lilly focused on displaying its latest progress in key global disease areas such as diabetes, obesity, Alzheimer’s disease and anti-tumor. In the big and comprehensive layout, Eli Lilly also revealed its two major focuses of development in China: diabetes and obesity, and Alzheimer’s disease. At this CIIE, Eli Lilly focused on displaying tirpotide. This is not surprising. As Eli Lilly’s flagship product, tirpotide is one of the most competitive GLP-1 drugs ...
- Source: drugdu
- 59
- November 7, 2024
Breaking news, Johnson & Johnson Medical Global Vice President resigns

Not long ago, Larry Jones, Global Vice President and Group Chief Information Officer of Johnson & Johnson MedTech, announced his decision to resign. On the LinkedIn platform, Jones recalled fondly: “Looking back on the 35 glorious years spent at Johnson & Johnson, my heart is filled with deep nostalgia for the extraordinary times we have gone through together.” During his tenure in Johnson & Johnson’s medical device department, Jones was particularly committed to promoting the company’s innovation in oncology, orthopedics, cardiovascular and general surgery, and realizing the innovation of digital surgical connection solutions through advanced technologies such as surgical robots and machine learning platforms. As a senior technology executive, Jones has rich leadership experience. During his decades in office, he has led many major projects in Johnson & Johnson’s pharmaceutical and medical device departments, including the recent three-year, $200 million global digital transformation plan. According to LinkedIn information, Jones is ...
- Source: drugdu
- 44
- November 5, 2024
Is the turning point of “Cosmic Pharmaceutical Factory” coming?

In 2022, Pfizer’s annual revenue exceeded $100 billion, making it the world’s largest pharmaceutical company in terms of revenue. However, as the COVID-19 pandemic quickly receded, revenue fell by 41% in 2023, and revenue ranking also dropped from first to fourth. Recently, the well-known radical investment institution Starboard Value invested $1 billion in Pfizer. What changes will this bring to this pharmaceutical giant? In 1849, Charles Pfizer and Charles Erhart founded Pfizer in New York, initially focusing on the production of chemical products. During World War II, Pfizer successfully mass-produced penicillin and launched oxytetracycline, officially entering the pharmaceutical industry. Since then, Pfizer has continued to expand through research and development and mergers and acquisitions, launched blockbuster drugs such as Norvasc and Viagra, and gradually became a leading global pharmaceutical company. Since the 21st century, Pfizer has topped the list of the top 50 pharmaceutical companies in the world (Pharm Exec ...
- Source: drugdu
- 64
- November 2, 2024
Million-RMB-worth CAR-T Drugs Miss Out on Health Insurance Negotiations for the Fourth Time

This morning, the much-anticipated on-site negotiations for the 2024 National Health Insurance Drug List adjustment concluded. According to First Financial News, CAR-T drugs have once again been absent from this round of negotiations, marking the fourth consecutive time they have not participated. “None of us appeared at the health insurance negotiation site,” a representative from a CAR-T company told First Financial News. The latest negotiations began on October 27, with 25 health insurance negotiation experts divided into five groups, negotiating and bidding for 162 types of drugs. The list of drugs under negotiation included commonly used medications for diabetes, hypertension, and infections, as well as medications for tumors and rare diseases. The final results of the on-site negotiations and bidding will be announced separately. Earlier, on August 27, the National Health Insurance Administration published a notice regarding the drug list adjustments for the 2024 National Basic Health Insurance, Work Injury ...
- Source: drugdu
- 74
- November 1, 2024
The second day of the 2024 National Negotiations | Hengrui, CSPC Pharmaceutical, Qilu Pharmaceutical, AstraZeneca…appeared! Antidiabetic and tumor drugs may be the focus

The 2024 National Medical Insurance Negotiations entered the second day. Beijing was sunny. On this day, antidiabetic and tumor drugs were the highlights. On the second day of the National Negotiations, Huang Bin, Vice President of AstraZeneca China, and Xia Yu, founder, chairman, president and CEO of Kangfang Bio, appeared at the National Negotiations. On the morning of October 28, the companies participating in the negotiations included AstraZeneca, Hengrui, Xinlitai, Hisun, CSPC Pharmaceutical, etc.; in the afternoon, Zhejiang Jingxin Pharmaceutical, Union Qilin, Beijing Novartis, Luye Pharmaceutical, Jiangsu Hausen, Bristol-Myers Squibb, Qilu, Changchun Jinsai, Zejing Bio, Hengrui, Novo Nordisk, etc. were present. Some on-site observers said that anti-tumor, antidiabetic and other chronic disease drugs were the protagonists of the second day of the National Negotiations. The National Medical Insurance Administration has carried out adjustments to the medical insurance drug list for six consecutive years, adding a total of 744 drugs to ...
- Source: drugdu
- 57
- October 30, 2024
1.596 billion, this pharmaceutical company was acquired

On the evening of October 21, Sichuan Shuangma announced that it plans to use its own and self-raised funds to acquire 92.1745% of Jianyuan Pharmaceutical’s equity for a total of 1.596 billion yuan. On October 22, Sichuan Shuangma opened at the daily limit, with a total market value of more than 14.3 billion yuan. Sichuan Shuangma was formerly known as Sichuan Shuangma Cement Co., Ltd. It was initially a building materials company focusing on the production and sales of cement products and building aggregates. It was listed on the main board of the Shenzhen Stock Exchange in 1999, and then gradually developed into a listed company engaged in industrial investment and private equity investment fund management. Its main managed assets include building materials manufacturing companies and private equity investment fund management companies. Sichuan Shuangma, born in the traditional industry, has not been optimistic about its recent development. The financial report ...
- Source: drugdu
- 59
- October 26, 2024
AI+drug target discovery | Insitro and Eli Lilly reach strategic agreement to jointly promote new therapies for metabolic diseases

Zhiyao Bang October 23, 2024 09:01 Shanghai On October 9, 2024, insitro, a new drug development company that supports machine learning, announced the signing of three strategic agreements with Eli Lilly, focusing on developing potential new drugs for the treatment of metabolic diseases, including metabolic dysfunction associated fatty liver (MASLD), based on the targets identified by insitro using the company’s AI based platform.Metabolic diseases, including MASLD, affect millions of people worldwide, but effective treatment options are still limited. The current treatment mainly treats the symptoms rather than the root cause. This collaboration aims to combine Insitro’s machine learning platform with Lilly’s expertise in cutting-edge drug delivery and metabolic disease biology to change existing models. According to the first two agreements, Insitro can choose to license Lilly’s proprietary, clinically advanced ternary N-acetylglucosamine (GalNAc) delivery technology, which will be combined with two different small interfering RNA (siRNA) molecules discovered and developed by ...
- Source: drugdu
- 74
- October 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.